All of our products are validated with standardised assays where available and are assessed in field by a wide number of laboratories so you can trust that the results are consistently reproducible in your laboratory. To view a full list of our products, head over to the products page. Alternatively, if you wish to find out more about our product pipeline, then please contact us.
The novel technology developed by HistoCyte Laboratories Ltd employs cell lines to avoid these issues and allows us to process the cell lines in to tissue-like controls. These controls also have the advantage of being manufactured to a reproducible standard and with inexhaustible supply. Our aim is to deliver this cost-effective control material to laboratories looking to improve confidence in their results and ultimately the service they offer. We will continue to expand our product range to include additional biomarkers, working closely with key opinion leaders in industry and academia to develop control material that is relevant and that provides confidence where it is most needed.
- Colin Tristram
Following the acquisition of Novocastra Laboratories Ltd by Vision BioSystems Ltd, Colin joined the commercial team expanding the sales of monoclonal antibodies and the Bond automated IHC/ISH platform throughout the UK, Europe and USA. As a consequence Colin developed a wide network of pathologists and researchers in many of the top hospitals and institutes enabling him to develop a Key Opinion Leader program and company publication reAGENTS.
After the acquisition of Vision Biosystems Ltd by the Danaher corporation Colin created the Innovation department at the Newcastle Leica Biosystems facility. The department was responsible for the qualification of projects from a clinical and commercial perspective prior to any R&D work. Over this period there was the development of class I and class III devices and wider collaborations with academics, clinicians and other companies within the biotech industry. Colin was instrumental in developing an Ideation process that worked for an IVD development work stream within the Danaher Business Systems Accelerated Development Process (APD).
As well as being a member of the Pathology Society of Great Britain and Ireland, Colin has previously been an assessor for UKNEQAS. Additionally, since 2010 Colin has been a Consultant and Guest Lecturer for the University of Newcastle upon Tyne at the Graduate School, Faculty of Medicine.
Head of Innovation, Leica Microsystems (acquired Vision Biosystems), Newcastle.
Market Development Manager, Vision Biosystems, Newcastle.
Corporate Accounts Manager - Europe, Vision Biosystems, Newcastle.
Technical Specialist, Vision Biosystems (acquired Novocastra), Newcastle.
Research Associate, Novocastra Laboratories Ltd, Newcastle
• Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ, Boyd EM, Hall M, Quinn A, Piggott N, Scorer P, Scott MA, Erber WN. Br J Haematol. 2009 Nov;147(4):495-506.
• Experimental validation of peptide immunohistochemistry controls.
Bogen SA, Vani K, McGraw B, Federico V, Habib I, Zeheb R, Luther E, Tristram C, Sompuram SR. Appl Immunohistochem Mol Morphol. 2009 May;17(3):239-46.
• The mouse tumor cell lines EL4 and RMA display mosaic expression of NK-related and certain other surface molecules and appear to have a common origin.
Gays F, Unnikrishnan M, Shrestha S, Fraser KP, Brown AR, Tristram CM, Chrzanowska-Lightowlers ZM, Brooks CG. J Immunol. 2000 May 15;164(10):5094-102.
- Ian Milton
Dr Milton has extensive experience in guiding fast growing organizations through post-acquisition cultural change and the transition from private to public ownership. In 2002, Novocastra was acquired by an Australian company, Vision BioSystems Ltd. This resulted in considerable change and growth for the Novocastra facility now called Vision BioSystems Newcastle Ltd. Subsequently in 2007 Vision BioSystems Ltd was acquired by the Danaher Corporation and incorporated into Leica Microsystems to create the Biosystems Division Leica Biosystems Newcastle Ltd.
Each acquisition was with a back drop of great regulatory change in the EU, USA and China. This provided Dr Milton with experience in the implementation of changes required to transform the company to comply with ISO design and manufacturing standards and conformity to FDA and SFDA standards and subsequent release of IVD labeled products.
Chief Scientific Officer, Leica Biosystems Newcastle Ltd.
Managing Director, Leica Biosystems Newcastle Ltd.
Research and Operations Director, Vision Biosystems Newcastle Ltd.
Research Director, Novocastra Laboratories Ltd.
Research and Development Manager, Novocastra Laboratories Ltd.
• A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues.
Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J. Hybridoma (Larchmt). 2007 Oct;26(5):281-8.
• Wild-type estrogen receptor beta expression in normal and neoplastic paraffin-embedded tissues.
Rees ML, Marshall I, McIntosh GG, Gray J, Mitchell K, Pinkney M, Piggott NH, Horne CH, Milton ID. Hybrid Hybridomics. 2004 Feb;23(1):11-8.
• NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue.
McIntosh GG, Lodge AJ, Watson P, Hall AG, Wood K, Anderson JJ, Angus B, Horne CH, Milton ID. Am J Pathol. 1999 Jan;154(1):77-82.
• The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study.
Fray AE, Ince PG, Banner SJ, Milton ID, Usher PA, Cookson MR, Shaw PJ. Eur J Neurosci. 1998 Aug;10(8):2481-9.
• Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study.
Milton ID, Banner SJ, Ince PG, Piggott NH, Fray AE, Thatcher N, Horne CH, Shaw PJ. Brain Res Mol Brain Res. 1997 Dec 1;52(1):17-31.
• New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry.
Bevitt DJ, Milton ID, Piggot N, Henry L, Carter MJ, Toms GL, Lennard TW, Westley B, Angus B, Horne CH. J Pathol. 1997 Oct;183(2):228-32.
• Production and characterization of a new monoclonal antibody effective in recognizing the CD3 T-cell associated antigen in formalin-fixed embedded tissue.
Steward M, Bishop R, Piggott NH, Milton ID, Angus B, Horne CH. Histopathology. 1997 Jan;30(1):16-22.
• Feline calicivirus strain differentiation using monoclonal antibody analysis in an enzyme-linked immuno-flow-assay.
McArdle F, Dawson S, Carter MJ, Milton ID, Turner PC, Meanger J, Bennett M, Gaskell RM. Vet Microbiol. 1996 Aug;51(3-4):197-206.
• Prokaryotic expression and analysis of the antibody response to a Newcastle isolate of the core gene of hepatitis C.
Milton ID, Watson JP, Guo K, Carter MJ, Bassendine MF, Toms GL. J Med Virol. 1995 Mar;45(3):253-8.
• A gene probe to detect feline calicivirus from tissue samples.
Meanger J, Dawson S, Milton ID, Carter MJ, Gaskell RM, Turner PC. Biochem Soc Trans. 1993 Nov;21(4):465S.
• An inexpensive and simple method for DNA purifications on silica particles.
Carter MJ, Milton ID. Nucleic Acids Res. 1993 Feb 25;21(4):1044.
• Scheme of RNA transcription in calicivirus-infected cells.
Meanger J, Carter MJ, Milton ID, Bennett M, Gaskell RM, Turner PC. Biochem Soc Trans. 1993 Feb;21(1):67S.
• Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from Staphylococcus xylosus.
Milton ID, Hewitt CL, Harwood CR. FEMS Microbiol Lett. 1992 Oct 1;76(1-2):141-7.
• The complete nucleotide sequence of a feline calicivirus.
Carter MJ, Milton ID, Meanger J, Bennett M, Gaskell RM, Turner PC. Virology. 1992 Sep;190(1):443-8.
• Location of monoclonal antibody binding sites in the capsid protein of feline calicivirus.
Milton ID, Turner J, Teelan A, Gaskell R, Turner PC, Carter MJ. J Gen Virol. 1992 Sep;73 (Pt 9):2435-9.
• Genomic 3' terminal sequence comparison of three isolates of rabbit haemorrhagic disease virus.
Milton ID, Vlasak R, Nowotny N, Rodak L, Carter MJ. FEMS Microbiol Lett. 1992 May 15;72(1):37-42.
• Identification and sequence determination of the capsid protein gene of feline calicivirus.
Carter MJ, Milton ID, Turner PC, Meanger J, Bennett M, Gaskell RM. Arch Virol. 1992;122(3-4):223-35.
Between 1974 and 1992 Dr. Colman enjoyed a successful university career in the Universities of Oxford, Warwick, Birmingham (where he was Professor of Biochemistry) and London (as mentioned above). He now lives in S.W France where, in addition to his professional commitments at Harvard and Genea Biocells, he is advisor to HistoCyte Laboratories Ltd. With his extensive cell biology knowledge and experience he is helping in their approach to applying the right cells to the various pathologies.
As part of Professor Hanby’s clinical commitment he directs the regional HER2 service originally providing tests for Leeds and the wider Yorkshire region. Initially providing a fluorescent in situ hybridization (FISH) service his service now provides dual-color dual-hapten brightfield in situ hybridization (DDISH) assay. The quality of the service is considered by the United Kingdom-National External Quality Assurance Scheme (UKNEQAS) to be of high quality and is a reference centre for HER2 in-situ hybridisation.
Professor Hanby is an assesor for UKNEQAS for the Her2 module as well as other markers. As a member of the National Health Service Breast Screening Programme (NHSBSP) Pathology BIG 18 Professor Hanby is helping to influence the standards and quality of breast pathology practice with benefits locally and nationally. With regard to Professor Hanby’s academic commitment, he is Deputy Head of Section of Pathology and Tumour Biology, Yorkshire Cancer Research and Liz Dawn Pathology and Translational Professor Hanby is an invited author for the World Health Organisation: classification of Tumours of the breast.
Professor McCluggage has an extremely busy referral practice and has been invited to lecture at numerous national and international meetings. Having authored or co-authored the various Royal College of Pathologists datasets in United Kingdom on reporting of gynaecological malignancies and having chaired the ICCR (International Collaboration in Cancer Reporting) panels developing international guidelines for reporting endometrial and ovarian carcinomas, he is currently chairing the ICCR panel developing the cervical cancer dataset. Glenn has been part of the last 2 WHO groups formulating the classification of Tumours of the Female Genital Tract and his main diagnostic interests are gynaecological malignancies and the uses of immunohistochemistry in gynaecological pathology.
Extensively published in his field Marco’s current areas of research include ploidy analysis in Barrett’s oesophagus, intra-abdominal stromal tumours and colorectal cancer. Frequently invited to speak at national and international meetings Marco also contributes to various books and is on the editorial board of a number of international journals.
By May 2016, Prof Salto-Tellez was author or co-author of more than 220 internationally peer-reviewed articles in translational science, molecular pathology and diagnostics, including work published in NEJM, Nature Medicine, Gastroenterology, FASEB, EMBO, Cancer Research and Clinical Cancer Research, among others. He has published a similar number of abstracts in international conferences, and is editor or contributor to some of the key textbooks of pathology and oncology. Professor Salto-Tellez studied Medicine in Spain (Oviedo), Germany (Aachen) and The Netherlands (Leiden). He specialized in Histopathology in the UK (Edinburgh and London) and in Molecular Pathology in USA (Philadelphia). For more than 10 years he worked at the National University of Singapore and its National University Hospital, where he was associate professor, senior consultant, director of the Diagnostic Molecular Oncology Centre, Vice-dean for Research and senior scientist at the Cancer Research Institute.
Prof Salto-Tellez serves on a number of committees nationally and internationally. His academic work has been recognised on numerous occasions and is reflected by his membership to the editorial boards of several journals. At present he holds more than £4.9M in active and competitive grant funding and currently leads the Northern Ireland – Molecular Pathology Laboratory (NI-MPL). The CPA accredited MPL is responsible for the molecular diagnostics of the whole of Northern Ireland.
For more information contact firstname.lastname@example.org